JP5844045B2 - 疾病の薬理シャペロン治療に対する応答性を予測する方法 - Google Patents

疾病の薬理シャペロン治療に対する応答性を予測する方法 Download PDF

Info

Publication number
JP5844045B2
JP5844045B2 JP2010546901A JP2010546901A JP5844045B2 JP 5844045 B2 JP5844045 B2 JP 5844045B2 JP 2010546901 A JP2010546901 A JP 2010546901A JP 2010546901 A JP2010546901 A JP 2010546901A JP 5844045 B2 JP5844045 B2 JP 5844045B2
Authority
JP
Japan
Prior art keywords
activity
gala
host cell
pharmacological chaperone
gal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010546901A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011514152A (ja
Inventor
エルフリダ・ベンジャミン
ブイ・ハング・ド
ウ・シャオヤン
ジョン・フラナガン
ブランドン・ウストマン
Original Assignee
アミカス セラピューティックス インコーポレイテッド
アミカス セラピューティックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40957500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5844045(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アミカス セラピューティックス インコーポレイテッド, アミカス セラピューティックス インコーポレイテッド filed Critical アミカス セラピューティックス インコーポレイテッド
Publication of JP2011514152A publication Critical patent/JP2011514152A/ja
Application granted granted Critical
Publication of JP5844045B2 publication Critical patent/JP5844045B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/94—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
JP2010546901A 2008-02-12 2009-02-12 疾病の薬理シャペロン治療に対する応答性を予測する方法 Active JP5844045B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US2814108P 2008-02-12 2008-02-12
US61/028,141 2008-02-12
US3568408P 2008-03-11 2008-03-11
US61/035,684 2008-03-11
US9363108P 2008-09-02 2008-09-02
US61/093,631 2008-09-02
US11349608P 2008-11-11 2008-11-11
US61/113,496 2008-11-11
PCT/US2009/033963 WO2009102895A2 (en) 2008-02-12 2009-02-12 Method to predict response to pharmacological chaperone treatment of diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014244283A Division JP2015091239A (ja) 2008-02-12 2014-12-02 疾病の薬理シャペロン治療に対する応答性を予測する方法

Publications (2)

Publication Number Publication Date
JP2011514152A JP2011514152A (ja) 2011-05-06
JP5844045B2 true JP5844045B2 (ja) 2016-01-13

Family

ID=40957500

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2010546901A Active JP5844045B2 (ja) 2008-02-12 2009-02-12 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2014244283A Pending JP2015091239A (ja) 2008-02-12 2014-12-02 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2016039171A Active JP6672013B2 (ja) 2008-02-12 2016-03-01 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2018245609A Active JP6837469B2 (ja) 2008-02-12 2018-12-27 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2021019383A Active JP7277493B2 (ja) 2008-02-12 2021-02-09 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2023076515A Withdrawn JP2023109807A (ja) 2008-02-12 2023-05-08 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2025097940A Pending JP2025148351A (ja) 2008-02-12 2025-06-11 疾病の薬理シャペロン治療に対する応答性を予測する方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2014244283A Pending JP2015091239A (ja) 2008-02-12 2014-12-02 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2016039171A Active JP6672013B2 (ja) 2008-02-12 2016-03-01 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2018245609A Active JP6837469B2 (ja) 2008-02-12 2018-12-27 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2021019383A Active JP7277493B2 (ja) 2008-02-12 2021-02-09 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2023076515A Withdrawn JP2023109807A (ja) 2008-02-12 2023-05-08 疾病の薬理シャペロン治療に対する応答性を予測する方法
JP2025097940A Pending JP2025148351A (ja) 2008-02-12 2025-06-11 疾病の薬理シャペロン治療に対する応答性を予測する方法

Country Status (16)

Country Link
US (8) US8592362B2 (OSRAM)
EP (4) EP3824900A1 (OSRAM)
JP (7) JP5844045B2 (OSRAM)
AU (7) AU2009214648B2 (OSRAM)
CA (1) CA2715407C (OSRAM)
CY (3) CY1116466T1 (OSRAM)
DK (3) DK3470077T3 (OSRAM)
ES (3) ES2541933T3 (OSRAM)
HR (3) HRP20150728T1 (OSRAM)
HU (3) HUE042882T2 (OSRAM)
LT (2) LT3470077T (OSRAM)
MX (1) MX2010008835A (OSRAM)
PL (3) PL2946785T3 (OSRAM)
PT (3) PT2252313E (OSRAM)
SI (3) SI2252313T1 (OSRAM)
WO (1) WO2009102895A2 (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007137072A2 (en) 2006-05-16 2007-11-29 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for fabry disease
AU2009214648B2 (en) 2008-02-12 2014-11-13 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
JP2011517556A (ja) * 2008-03-12 2011-06-16 アミカス セラピューティックス インコーポレイテッド ポンペ病のための治療選択肢を診断し評価するための検定
AR078498A1 (es) * 2009-10-01 2011-11-09 Baylor Res Inst Tratamiento de calvicie de patron masculino por induccion local del defecto metabolico de la enfermedad de fabry
US20120283290A1 (en) * 2011-05-06 2012-11-08 Amicus Therapeutics Inc. Quantitation of gl3 in urine
DK3201320T5 (da) 2014-09-30 2024-10-14 Amicus Therapeutics Inc Højpotent sur alfa-glucosidase med forbedrede carbohydrater
CA2979695C (en) 2015-03-19 2025-02-06 Translate Bio Inc RNA THERAPY FOR POMPE DISEASE
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
MX394968B (es) 2015-12-30 2025-03-24 Amicus Therapeutics Inc Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe.
PL3957320T3 (pl) 2015-12-30 2024-02-19 Amicus Therapeutics, Inc. Wzmocniona kwaśna alfa-glukozydaza do leczenia choroby Pompego
WO2017165164A1 (en) 2016-03-22 2017-09-28 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
KR102343162B1 (ko) * 2016-03-30 2021-12-23 아미쿠스 세라퓨틱스, 인코포레이티드 고 m6p 재조합 단백질의 선택 방법
HRP20220817T1 (hr) 2016-03-30 2022-09-30 Amicus Therapeutics, Inc. Formulacije koje sadrže rekombinantnu kiselu alfa-glukozidazu
CA3019128A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
TWI875676B (zh) 2016-07-19 2025-03-11 美商阿米庫斯醫療股份有限公司 治療ert初治的和已經歷ert的患者中之法布瑞氏症
JP6546135B2 (ja) 2016-08-24 2019-07-17 株式会社ノリタケカンパニーリミテド 積層造形焼成体、積層造形焼成体の製造方法および積層造形焼成体製造用キット
AU2017345430B2 (en) * 2016-10-20 2024-09-05 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of Fabry disease
EA202290114A1 (ru) * 2017-03-30 2022-03-29 Амикус Терапьютикс, Инк. Способ отбора рекомбинантных белков с высоким содержанием m6p
SMT202300187T1 (it) 2017-05-15 2023-07-20 Amicus Therapeutics Inc Alfa-glucosidasi acida umana ricombinante
TWI795408B (zh) 2017-05-30 2023-03-11 美商阿米庫斯醫療股份有限公司 治療有腎損傷的法布里患者的方法
CA3224529A1 (en) 2017-05-30 2018-12-06 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
SG11202000423XA (en) 2017-07-19 2020-02-27 Amicus Therapeutics Inc Treatment of fabry disease in ert-naïve and ert-experienced patients
CN111770753A (zh) 2017-08-28 2020-10-13 阿米库斯治疗学公司 增强和/或稳定患有法布里病患者的心脏功能的方法
JP2021512896A (ja) 2018-02-06 2021-05-20 アミカス セラピューティックス インコーポレイテッド 古典型ファブリー病患者の治療
CA3090496C (en) 2018-02-06 2024-03-26 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
ES2993833T3 (en) 2018-08-20 2025-01-10 Amicus Therapeutics Inc Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene
NL2021840B1 (en) 2018-10-19 2020-05-13 Univ Leiden Pharmacological Chaperones For Enzyme Treatment Therapy
WO2020046132A1 (en) 2018-08-31 2020-03-05 Leiden University Pharmacological chaperones for enzyme treatment therapy
TW202042812A (zh) 2019-01-22 2020-12-01 美商阿米庫斯醫療股份有限公司 減少法布瑞氏症患者中之腦血管事件之方法
US20220313670A1 (en) 2019-06-11 2022-10-06 Amicus Therapeutics, Inc. Methods Of Treating Fabry Disease In Patients Having Renal Impairment
US11833164B2 (en) * 2019-08-07 2023-12-05 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
EP4025242A1 (en) 2019-09-06 2022-07-13 Amicus Therapeutics, Inc. Method for capturing and purification of biologics
SI4114390T1 (sl) * 2020-03-06 2025-03-31 Amicus Therapeutics, Inc. Postopki zdravljenja Fabryjeve bolezni pri bolnikih z mutacijo gena GLA
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
AU2022310691A1 (en) 2021-07-12 2024-01-25 Amicus Therapeutics, Inc. Methods of treating fabry disease in pediatric patients
AU2023265155A1 (en) 2022-05-05 2024-12-12 Amicus Therapeutics, Inc. Methods for treating pompe disease
CN121057588A (zh) 2022-12-02 2025-12-02 阿米库斯治疗学公司 用于在儿科患者中治疗迟发性庞贝病的方法
AU2023406510A1 (en) 2022-12-02 2025-07-10 Amicus Therapeutics, Inc. Fexamethods for treating infantile-onset pompe disease in pediatric patients
US20240197706A1 (en) 2022-12-13 2024-06-20 Amicus Therapeutics, Inc. Methods of improving the pharmacokinetics of migalastat

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21381A (en) * 1858-08-31 Bracelet
US203019A (en) * 1878-04-30 Improvement in circuits for acoustic or telephonic telegraphs
US264467A (en) * 1882-09-19 Chables h
US270486A (en) * 1883-01-09 Bundle-separating attachment for self-binding harvesters
US3586908A (en) 1969-02-28 1971-06-22 Robert E Vosteen Automatic potential control system for electrophotography apparatus
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5863903A (en) 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
US5844102A (en) 1994-07-07 1998-12-01 University Of Maryland Baltimore County Glycohydrolase inhibitors, their preparation and use thereof
JP2000509971A (ja) 1996-04-10 2000-08-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 化学的シャペローンを用いる遺伝的欠陥の修正
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US5948653A (en) 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US6244113B1 (en) 1999-10-29 2001-06-12 University Of Alabama In Huntsville Method and apparatus for measuring microgravity acceleration
US7842470B2 (en) * 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
ES2572148T3 (es) * 2005-05-17 2016-05-30 Amicus Therapeutics Inc Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados
EP2027137B1 (en) 2005-06-08 2015-02-18 Amicus Therapeutics, Inc. Imino and amino sugar purification
CN104771402A (zh) * 2005-06-08 2015-07-15 阿米库斯治疗学公司 溶酶体酶编码基因突变相关的cns紊乱的治疗
US7790364B2 (en) * 2006-01-27 2010-09-07 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for high throughput screening of pharmacological chaperones
WO2007137072A2 (en) 2006-05-16 2007-11-29 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for fabry disease
PT1860101E (pt) 2006-05-24 2011-07-12 Amicus Therapeutics Inc Sal de tartrato da isofagomina e métodos de uso
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2008134628A2 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
AU2009214648B2 (en) 2008-02-12 2014-11-13 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
US8321148B2 (en) 2008-10-24 2012-11-27 Amicus Therapeutics, Inc. Multiple compartment dosing model
US9206457B2 (en) 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
ES2585584T3 (es) 2009-05-26 2016-10-06 Amicus Therapeutics, Inc. Utilización de chaperonas farmacológicas para mejorar la fabricación y la purificación de ß-glucosidasa ácida
WO2011063048A2 (en) 2009-11-17 2011-05-26 Baylor Research Institute Urinary triaosylceramide (gb3) as a marker of cardiac disease
CN107088225A (zh) 2011-03-11 2017-08-25 阿米库斯治疗学公司 治疗法布里病的给药方案
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
WO2014014938A1 (en) 2012-07-17 2014-01-23 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
WO2017165164A1 (en) 2016-03-22 2017-09-28 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
TWI875676B (zh) 2016-07-19 2025-03-11 美商阿米庫斯醫療股份有限公司 治療ert初治的和已經歷ert的患者中之法布瑞氏症
WO2018132471A1 (en) 2017-01-10 2018-07-19 Amicus Therapeutics, Inc. Recombinant alpha-galactosidase a for treatment of fabry disease
CA3224529A1 (en) 2017-05-30 2018-12-06 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
SG11202000423XA (en) 2017-07-19 2020-02-27 Amicus Therapeutics Inc Treatment of fabry disease in ert-naïve and ert-experienced patients
CN111770753A (zh) 2017-08-28 2020-10-13 阿米库斯治疗学公司 增强和/或稳定患有法布里病患者的心脏功能的方法
JP2021512896A (ja) 2018-02-06 2021-05-20 アミカス セラピューティックス インコーポレイテッド 古典型ファブリー病患者の治療
CA3090496C (en) 2018-02-06 2024-03-26 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
ES2993833T3 (en) 2018-08-20 2025-01-10 Amicus Therapeutics Inc Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene
US20220313670A1 (en) 2019-06-11 2022-10-06 Amicus Therapeutics, Inc. Methods Of Treating Fabry Disease In Patients Having Renal Impairment
US11833164B2 (en) 2019-08-07 2023-12-05 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene

Also Published As

Publication number Publication date
PT2946785T (pt) 2019-02-01
EP2252313A2 (en) 2010-11-24
AU2009214648B2 (en) 2014-11-13
SI2252313T1 (sl) 2015-08-31
JP6837469B2 (ja) 2021-03-03
ES2541933T3 (es) 2015-07-28
US10813921B2 (en) 2020-10-27
AU2014221321B2 (en) 2016-05-12
AU2024219997A1 (en) 2024-10-10
US20210251971A1 (en) 2021-08-19
CY1121386T1 (el) 2020-05-29
MX2010008835A (es) 2010-10-20
EP3470077A1 (en) 2019-04-17
CY1123816T1 (el) 2022-03-24
DK3470077T3 (da) 2020-11-30
CA2715407A1 (en) 2009-08-20
USRE48608E1 (en) 2021-06-29
WO2009102895A2 (en) 2009-08-20
LT3470077T (lt) 2021-02-25
CY1116466T1 (el) 2017-03-15
US20110152319A1 (en) 2011-06-23
HRP20150728T1 (hr) 2015-08-14
JP2011514152A (ja) 2011-05-06
US20190000818A1 (en) 2019-01-03
AU2016206297A1 (en) 2016-08-04
HUE051377T2 (hu) 2021-03-01
US20150342940A1 (en) 2015-12-03
AU2017268649A1 (en) 2018-01-04
DK2946785T3 (en) 2019-02-18
AU2014221321A1 (en) 2014-10-02
PT2252313E (pt) 2015-08-26
EP2946785B1 (en) 2018-10-24
JP2025148351A (ja) 2025-10-07
JP2023109807A (ja) 2023-08-08
US20110212996A1 (en) 2011-09-01
US20250082621A9 (en) 2025-03-13
PL2252313T3 (pl) 2015-09-30
EP3470077B1 (en) 2020-08-26
JP2016163571A (ja) 2016-09-08
ES2836121T3 (es) 2021-06-24
CA2715407C (en) 2022-07-26
EP2946785A1 (en) 2015-11-25
US9545397B2 (en) 2017-01-17
AU2019219727A1 (en) 2019-09-12
SI2946785T1 (sl) 2019-02-28
AU2009214648A1 (en) 2009-08-20
AU2021218172A1 (en) 2021-10-07
EP2252313A4 (en) 2011-04-13
JP2019088289A (ja) 2019-06-13
HRP20190143T1 (hr) 2019-03-22
HUE042882T2 (hu) 2019-07-29
JP6672013B2 (ja) 2020-03-25
EP3824900A1 (en) 2021-05-26
ES2716502T3 (es) 2019-06-12
PT3470077T (pt) 2020-11-30
JP2021097673A (ja) 2021-07-01
JP2015091239A (ja) 2015-05-14
HUE026543T2 (hu) 2016-06-28
US9095584B2 (en) 2015-08-04
JP7277493B2 (ja) 2023-05-19
PL2946785T3 (pl) 2019-04-30
SI3470077T1 (sl) 2020-12-31
US8592362B2 (en) 2013-11-26
AU2019219727B2 (en) 2021-05-20
LT2946785T (lt) 2019-02-11
PL3470077T3 (pl) 2021-04-06
HRP20201827T1 (hr) 2021-01-08
DK2252313T3 (en) 2015-07-13
US20170003301A1 (en) 2017-01-05
EP2252313B1 (en) 2015-04-08
US20140206721A1 (en) 2014-07-24
WO2009102895A3 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
JP7277493B2 (ja) 疾病の薬理シャペロン治療に対する応答性を予測する方法
HK40053489A (en) Method to predict response to pharmacological chaperone treatment of diseases
HK40007672A (en) Method to predict response to pharmacological chaperone treatment of diseases
HK40007672B (en) Method to predict response to pharmacological chaperone treatment of diseases

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131219

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20131219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140220

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20140417

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150928

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151020

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151118

R150 Certificate of patent or registration of utility model

Ref document number: 5844045

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250